Allianz Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.27M Hold
379,805
﹤0.01% 1359
2026
Q1
$5.27M Buy
379,805
+55,420
+17% +$883K 0.01% 1138
2025
Q4
$5.27M Buy
324,385
+2,611
+0.8% +$42.6K 0.01% 1119
2025
Q3
$4.81M Buy
321,774
+242,474
+306% +$2.95M 0.01% 1132
2025
Q2
$924K Buy
79,300
+66,500
+520% +$604K ﹤0.01% 1687
2025
Q1
$95.1K Buy
12,800
+100
+0.8% +$769 ﹤0.01% 2177
2024
Q4
$76.1K Buy
+12,700
New +$70K ﹤0.01% 2156
2022
Q2
Sell
-366,290
Closed -$5.08M 2252
2022
Q1
$5.08M Sell
366,290
-35,215
-9% -$554K ﹤0.01% 1221
2021
Q4
$11.3M Sell
401,505
-46,530
-10% -$1.43M 0.01% 951
2021
Q3
$15.2M Sell
448,035
-17,694
-4% -$640K 0.01% 839
2021
Q2
$19M Buy
465,729
+405,482
+673% +$15.8M 0.02% 663
2021
Q1
$2.42M Sell
60,247
-351,887
-85% -$19M ﹤0.01% 1337
2020
Q4
$24.4M Buy
412,134
+105,569
+34% +$5.44M 0.02% 549
2020
Q3
$14.9M Buy
306,565
+60,860
+25% +$2.56M 0.02% 659
2020
Q2
$11.9M Buy
245,705
+224,347
+1,050% +$8.18M 0.01% 819
2020
Q1
$593K Sell
21,358
-13,039
-38% -$364K ﹤0.01% 1987
2019
Q4
$1.03M Sell
34,397
-28,174
-45% -$809K ﹤0.01% 2183
2019
Q3
$1.93M Sell
62,571
-141,234
-69% -$5.76M ﹤0.01% 1837
2019
Q2
$9.84M Buy
+203,805
New +$9.03M 0.01% 1199

Other funds holding ADPT

Allianz Asset Management's ADPT Position: Q2 2026 in Review

Allianz Asset Management held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 379,805 shares worth $5.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1359.

Allianz Asset Management first reported a position in ADPT in Q2 2019 and has held it in 19 quarters since. The position peaked at $24.4M in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Allianz Asset Management held 379,805 shares of Adaptive Biotechnologies worth $5.27M as of Q2 2026.
  • Allianz Asset Management left its Adaptive Biotechnologies share count unchanged in Q2 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1359 holding.
  • Allianz Asset Management first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 19 quarters since.
  • Allianz Asset Management's Adaptive Biotechnologies position peaked at $24.4M in Q4 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.